News : Basilea

Oct 10. 2024

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year

Sep 24. 2024

Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis

Sep 19. 2024 / Ad hoc announcement

Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding

Sep 06. 2024 / Ad hoc announcement

Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea

Aug 27. 2024 / Ad hoc announcement

European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea

Aug 21. 2024

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Aug 13. 2024 / Ad hoc announcement

Basilea reports strong 2024 half-year results and significantly increases full-year revenue and profit guidance

Jun 20. 2024

Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation

May 16. 2024

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

May 03. 2024

Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024

Apr 24. 2024

Basilea shareholders approve all proposals of the board of directors at the annual general meeting

Apr 09. 2024

Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics

Apr 04. 2024 / Ad hoc announcement

Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications

Mar 11. 2024

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Feb 13. 2024 / Ad hoc announcement

Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio

Jan 19. 2024

Cresemba® sales in Latin America trigger first sales milestone payment to Basilea

Jan 15. 2024

Basilea announces acquisition of preclinical antibiotics program from Spexis

Jan 05. 2024

Basilea provides portfolio status update

Dec 20. 2023 / Ad hoc announcement

Basilea announces accelerated loan repayment

Dec 11. 2023

Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis

Nov 20. 2023

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year

Nov 13. 2023 / Ad hoc announcement

Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal

Oct 31. 2023 / Ad hoc announcement

Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent

Oct 19. 2023 / Ad hoc announcement

Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infections

Oct 17. 2023

Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023

Oct 02. 2023 / Ad hoc announcement

Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole

Sep 28. 2023

Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia

Aug 15. 2023 / Ad hoc announcement

Basilea reports strong revenue and profit growth in first half-year 2023

Aug 04. 2023 / Ad hoc announcement

Basilea announces submission of a New Drug Application to the US Food and Drug Administration for its antibiotic ceftobiprole

Jun 08. 2023 / Ad hoc announcement

Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 26 million sales milestone payments to Basilea

Apr 26. 2023

Basilea shareholders approve all proposals of the board of directors at the annual general meeting

Apr 18. 2023 / Ad hoc announcement

Basilea provides update on New Drug Application to the US Food and Drug Administration for antibiotic ceftobiprole

Mar 23. 2023

Basilea announces CHF 5 million milestone payment from Asahi Kasei Pharma for antifungal Cresemba® (isavuconazole) in Japan

Feb 14. 2023 / Ad hoc announcement

Basilea reports strong financial results 2022 based on successful implementation of new strategy

Feb 07. 2023

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers second sales milestone payment to Basilea from Pfizer

Jan 24. 2023 / Ad hoc announcement

Basilea reports preliminary operating profit for 2022, significantly above guidance

Jan 11. 2023 / Ad hoc announcement

Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update

Jan 09. 2023 / Ad hoc announcement

Continued strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 20 million sales milestone payment to Basilea

Dec 28. 2022

Basilea announces repayment of 2022 convertible bonds

Dec 23. 2022

Basilea announces regulatory approval of antifungal Cresemba® (isavuconazole) in Japan

Dec 19. 2022

Basilea announces transition milestone for oncology asset BAL0891, triggering milestone payment of USD 4 million by SillaJen

Nov 02. 2022

Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutics

Oct 24. 2022

ERADICATE phase 3 study results highlight the potential role of ceftobiprole in the treatment of Staphylococcus aureus bacteremia (SAB)

Oct 13. 2022

Basilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus bacteremia (SAB) at IDWeek 2022

Sep 21. 2022

Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium

Sep 20. 2022 / Ad hoc announcement

Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and updates financial guidance

Sep 08. 2022

Basilea announces sale of preclinical oncology program to Nodus Oncology

Sep 07. 2022 / Ad hoc announcement

Basilea announces CHF 75 million senior secured loan agreement with Athyrium for non-dilutive refinancing of convertible bonds due in December 2022

Aug 16. 2022 / Ad hoc announcement

Basilea reports strong financial half-year results and progress in the implementation of new anti-infectives strategy

Jul 12. 2022

Basilea announces Zevtera® (ceftobiprole) marketing authorization in Brazil

Jun 28. 2022 / Ad hoc announcement

Basilea announces positive results of phase 3 ERADICATE study with ceftobiprole in Staphylococcus aureus bacteremia (SAB)

Jun 27. 2022 / Ad hoc announcement

Basilea reports progress on the implementation of its strategy to focus on anti-infectives

Jun 24. 2022

Basilea announces approval for additional formulation of antifungal Cresemba® (isavuconazole) in China

Jun 17. 2022

Cresemba® sales in Asia Pacific region trigger sales milestone payment to Basilea from Pfizer

Apr 27. 2022

Basilea announces licensing of a novel first-in-class antifungal program from Fox Chase Chemical Diversity Center

Apr 13. 2022

Basilea shareholders approve all proposals of the board of directors at the annual general meeting

Apr 13. 2022

Basilea reports preclinical data on oncology drug candidates BAL0891, derazantinib and lisavanbulin at AACR Annual Meeting

Mar 08. 2022

Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at ESMO TAT congress

Feb 15. 2022 / Ad hoc announcement

Basilea to become a leading anti-infectives company backed by strong financial results 2021

Jan 24. 2022

Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications from phase 2 study FIDES-01 at ASCO GI Cancers Symposium

Jan 13. 2022

Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in China

Jan 11. 2022

Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections

Jan 10. 2022 / Ad hoc announcement

Basilea exceeds 2021 financial guidance on preliminary revenue and year-end cash-position

Jan 07. 2022 / Ad hoc announcement

Strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million sales milestone payment to Basilea

Jan 06. 2022

Basilea reports on portfolio progress made in 2021

Dec 21. 2021 / Ad hoc announcement

Basilea receives USD 10 million milestone payment related to approval of antifungal Cresemba® (isavuconazole) in China

Dec 17. 2021 / Ad hoc announcement

Basilea announces FDA approval of Investigational New Drug application for novel oncology drug candidate BAL0891

Dec 08. 2021 / Ad hoc announcement

Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 10 million sales milestone payment to Basilea

Nov 16. 2021

Basilea announces submission of Investigational New Drug application for novel oncology drug candidate BAL0891

Oct 11. 2021

Basilea presents preclinical data on synergy between derazantinib and paclitaxel in gastric tumor models at ANE Conference

Sep 30. 2021 / Ad hoc announcement

Basilea’s partner Asahi Kasei Pharma filed New Drug Application for the marketing authorization of isavuconazole in Japan

Sep 17. 2021

Basilea presents full safety and efficacy data set on derazantinib in patients with FGFR2 fusion-positive iCCA at ESMO congress

Aug 17. 2021 / Ad hoc announcement

Basilea reports strong financial results for half-year 2021 with significantly increased cash flow from marketed brands and increases 2021 full-year guidance

Aug 16. 2021 / Ad hoc announcement

Basilea awarded additional USD 4.3 million by BARDA to support phase 3 development of ceftobiprole

Jul 29. 2021

Basilea announces U.S. FDA Orphan Drug Designation granted to lisavanbulin for the treatment of malignant glioma

Jul 26. 2021 / Ad hoc announcement

Basilea’s partner Asahi Kasei Pharma prepares NDA filing for the marketing authorization of isavuconazole in Japan based on positive phase 3 study results

Jul 14. 2021 / Ad hoc announcement

Basilea announces distribution agreement with JSC Lancet for antibiotic Zevtera® (ceftobiprole) covering Russia and the Eurasian Economic Union

Jun 07. 2021

Basilea reports new prevalence data for EB1, a potential response-predictive biomarker for lisavanbulin in glioblastoma and other tumor types, at ASCO Annual Meeting

May 31. 2021

Basilea provides updates on efficacy data with derazantinib in bile duct cancer and on ongoing clinical programs in urothelial and gastric cancer

May 19. 2021

Basilea awarded CARB-X grant of up to USD 2.7 million to develop novel-class antibiotic

Apr 21. 2021

Basilea shareholders approve all proposals of the board of directors at the annual general meeting

Apr 01. 2021

Basilea announces closing of previously announced transaction regarding divestment of its Chinese R&D subsidiary

Mar 24. 2021

Basilea reports positive interim results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene mutation- or amplification-positive patients with bile duct cancer (iCCA)

Feb 24. 2021

Basilea successfully placed 1 million new registered shares, raising gross proceeds of CHF 45.75 million

Read more Download

Feb 23. 2021

Basilea launches a private placement of new shares by way of an accelerated bookbuilding

Read more Download

Feb 16. 2021

Basilea reports strong 2020 financial results and significant progress in the clinical pipeline of its oncology assets

Feb 15. 2021

Basilea announces divestment of its Chinese R&D subsidiary to PHT International

Feb 12. 2021

Basilea reports derazantinib/PD-L1 checkpoint inhibitor combination results from dose-finding part of FIDES-02 study in patients with solid tumors at ASCO GU symposium

Feb 11. 2021

Basilea achieves preclinical milestone in oncology collaboration on potential first-in-class kinase inhibitor

Feb 10. 2021

Basilea reports positive topline results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene fusion-positive patients with bile duct cancer (iCCA)

Feb 09. 2021

Continued strong Cresemba® (isavuconazole) sales trigger milestone from Pfizer to Basilea of USD 10 million

Jan 11. 2021

Basilea reports preliminary 2020 revenue and portfolio progress

Jan 07. 2021

Basilea’s partner Asahi Kasei Pharma completes patient enrolment in phase 3 study with antifungal isavuconazole (Cresemba®) in Japan

Nov 25. 2020

Basilea reports acceptance for regulatory review of Pfizer’s marketing authorization application for antifungal isavuconazole (Cresemba®) in invasive aspergillosis in China

Nov 06. 2020

Basilea announces approval of antibiotic Zevtera® in China to treat community-acquired pneumonia and hospital-acquired pneumonia

Oct 28. 2020

Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ramucirumab in the ongoing FIDES-03 study with derazantinib in gastric cancer

Oct 26. 2020

Basilea presents preclinical data on anti-angiogenic activity of derazantinib at ENA 2020

Oct 13. 2020

Basilea reports interim results from phase 1/2 study FIDES-02 exploring derazantinib in patients with advanced urothelial cancer

Oct 12. 2020

Basilea reports pooled efficacy data for derazantinib in iCCA patients with FGFR2 gene mutations and amplifications presented at ESMO MAP Virtual Congress 2020

Sep 29. 2020

Basilea initiates targeted biomarker-driven phase 2 study with lisavanbulin in patients with brain cancer

Sep 28. 2020

Basilea starts phase 1/2 study FIDES-03 with derazantinib in patients with gastric cancer

Sep 22. 2020

Basilea reports data from poster presentations at ESMO Virtual Congress 2020

Aug 11. 2020

Basilea reports strong financial results for half-year 2020, progress in R&D portfolio and successful completion of strategic projects, despite COVID-19

Aug 07. 2020

Basilea reports acceptance for regulatory review of Pfizer’s marketing authorization application for antifungal isavuconazole (Cresemba®) in China

Jul 28. 2020

Basilea announces completion of its transaction involving a partial repurchase of its existing bond and the issuance of a new bond

Read more Download

Jul 28. 2020

Basilea announces data presentations at ESMO Virtual Congress 2020

Jul 21. 2020

Basilea announces a conversion price of CHF 62.50 for its New Bonds and the acceptance of tendered Bonds in an aggregated principal amount of approximately CHF 47 million

Read more Download

Jul 20. 2020

Basilea announces completion of patient enrolment into first cohort of phase 2 study FIDES-01 with derazantinib in bile duct cancer (iCCA)

Jul 17. 2020

Basilea continues with the implementation of the Repurchase Offer and the issuance of New Bonds

Read more Download

Jul 17. 2020

Basilea Bonds tendered in an aggregate principal amount of approximately CHF 47 million

Read more Download

Jul 15. 2020

Basilea reports the launch of antifungal Cresemba® (isavuconazole) in Taiwan, triggering the second milestone payment related to Asia-Pacific

Jul 10. 2020

Basilea announces the start of the offer period of its partial repurchase offer for its outstanding convertible bonds due 2022

Read more Download

Jun 30. 2020

Basilea announces move of corporate headquarters to Allschwil, canton of Basel-Landschaft, in 2022

Jun 25. 2020

Basilea announces partial repurchase offer for at least CHF 90 million and up to CHF 110 million in principal amount of its outstanding convertible bonds due 2022

Read more Download

Jun 24. 2020

Basilea successfully places CHF 125 million senior convertible bonds

Read more Download

Jun 24. 2020

Basilea launches the placement of CHF 100 million senior convertible bonds with an increase option of CHF 25 million

Read more Download

Jun 23. 2020

Basilea enters into sale and leaseback agreement for corporate headquarters building

Jun 22. 2020

Basilea receives CHF 5 million milestone payment related to marketing authorization of antifungal Cresemba® in Russia

May 28. 2020

Basilea provides corporate update

Apr 29. 2020

Basilea announces appointment of new Head of Global Quality Management

Apr 08. 2020

Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting

Feb 27. 2020

Basilea reports the launch of antifungal Cresemba® (isavuconazole) in Australia triggering the first milestone payment related to Asia-Pacific

Feb 18. 2020

Basilea reports significant revenue growth from marketed products and pipeline progress for full-year 2019

Jan 23. 2020

Basilea reports activity of derazantinib in preclinical models of gastric cancer at ASCO Gastrointestinal Cancers Symposium

Jan 22. 2020

Basilea announces clinical supply agreement for its planned study FIDES-03 with derazantinib in gastric cancer

Jan 10. 2020

Basilea reports total revenue exceeding guidance driven by higher than expected contributions from Cresemba® and Zevtera® in 2019

Jan 08. 2020

Basilea at the 38th Annual J. P. Morgan Healthcare Conference – significant progress in Cresemba commercialization and R&D portfolio in 2019

Dec 16. 2019

Basilea plans progression of oncology candidate lisavanbulin to targeted, biomarker-driven phase 2 study

Dec 06. 2019

Continued strong Cresemba® (isavuconazole) sales trigger second sales milestone this year from Pfizer to Basilea of USD 7 million

Oct 30. 2019

Basilea reports positive preclinical data on oncology drug candidates derazantinib and lisavanbulin at AACR-NCI-EORTC conference

Oct 29. 2019

Basilea reports marketing authorization of antifungal Cresemba® in Brazil

Sep 30. 2019

Basilea reports at ESMO meeting that drug candidate derazantinib showed clinical benefit in intrahepatic cholangiocarcinoma (iCCA) patients with various FGFR2 genetic aberrations

Aug 27. 2019

Basilea announces completion of patient enrolment in phase 1 study with oral BAL101553 in brain cancer

Aug 20. 2019

Basilea reports significantly increased cash-generating revenue, flat operating expenses and reduced net loss for half-year 2019

Aug 13. 2019

Basilea starts phase 1/2 study with derazantinib in urothelial cancer

Aug 06. 2019

Basilea announces positive results of phase 3 TARGET study with antibiotic ceftobiprole in the treatment of acute bacterial skin and skin structure infections (ABSSSI)

Jul 01. 2019

Basilea extends phase 2 study with derazantinib in intrahepatic bile duct cancer (iCCA) to include patients with FGFR2 gene mutations or amplifications

Jun 03. 2019

Basilea reports publication of clinical data for anticancer drug candidates BAL101553 in glioblastoma and derazantinib in intrahepatic cholangiocarcinoma at ASCO meeting

May 02. 2019

Basilea's partner Avir Pharma has launched antifungal Cresemba® (isavuconazole) in Canada

Apr 12. 2019

Basilea reports isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Apr 10. 2019

Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting

Feb 19. 2019

Basilea reports strong revenue growth and significant pipeline progress for full-year 2018

Feb 08. 2019

Strong European Cresemba® (isavuconazole) sales trigger USD 5 million milestone payment to Basilea from Pfizer

Feb 07. 2019

Basilea announces change in the Management Committee - Adesh Kaul appointed CFO

Jan 24. 2019

Basilea announces collaboration to study derazantinib and atezolizumab (Tecentriq®) in urothelial cancer

Jan 09. 2019

Basilea reports positive interim results from registrational phase 2 study with oncology drug candidate derazantinib in intrahepatic cholangiocarcinoma (iCCA)

Jan 07. 2019

Basilea reports strong, higher than expected preliminary revenue of CHF 133 million for financial year 2018

Jan 04. 2019

Basilea presenting at the 37th Annual J. P. Morgan Healthcare Conference - delivering on its strategy

Dec 10. 2018

Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea

Nov 14. 2018

Basilea presents preclinical data on its anticancer drug candidate BAL101553 at EORTC-NCI-AACR symposium

Aug 14. 2018

Basilea reports half-year financial results reflecting strong in-market product sales growth in addition to progress and expansion of the R&D pipeline

Aug 13. 2018

Basilea reports on first Cresemba® approval in MENA region

Aug 09. 2018

Basilea starts clinical phase 3 study with antibiotic ceftobiprole in Staphylococcus aureus bacteremia (SAB)

Jul 19. 2018

Basilea reports receipt of milestone payment based on first Cresemba® approval in Latin America

Jun 26. 2018

Basilea starts clinical phase 2a expansion with BAL101553 in ovarian cancer and glioblastoma

Jun 05. 2018

Basilea reports presentation of phase 1 clinical data with anticancer drug candidate BAL101553 at ASCO meeting

May 24. 2018

Basilea Pharmaceutica: Subscription to Basilea's Press Release Newsletter

May 15. 2018

Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Saudi Arabia by Hikma Pharmaceuticals LLC

Apr 27. 2018

Basilea announces appointment of Chief Technology Officer and appointment of Head of Global Quality Management

Apr 20. 2018

Basilea reports presentations of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Apr 19. 2018

Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting of Shareholders

Apr 18. 2018

Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavuconazole

Apr 17. 2018

Basilea licenses late-stage oncology drug candidate derazantinib from ArQule

Apr 09. 2018

Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Canada by Avir Pharma

Mar 06. 2018

Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Argentina by Grupo Biotoscana

Mar 01. 2018

Basilea names Adesh Kaul as new member of its Management Committee

Feb 27. 2018

Basilea reports significantly improved financial results in 2017

Feb 23. 2018

Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract

Feb 21. 2018

Basilea's CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of Directors

Jan 10. 2018

Basilea announces completion of the license agreement extension with Pfizer for antifungal Cresemba® for China and Asia Pacific

Jan 03. 2018

Basilea reports start of clinical phase 1 study in collaboration with the U.S. Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma

Dec 21. 2017

Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of Staphylococcus aureus bacteremia (SAB)

Dec 01. 2017

Basilea extends existing license agreement with Pfizer for antifungal Cresemba® (isavuconazole) to China and Asia Pacific

Nov 02. 2017

Basilea reports on commercial progress of antifungal Cresemba® in Europe

Oct 31. 2017

Basilea's Chief Medical Officer Prof. Achim Kaufhold to retire and Dr. Marc Engelhardt named as successor

Oct 23. 2017

Strong Cresemba® (isavuconazole) sales in the United States trigger first sales milestone payment to Basilea

Sep 28. 2017

Basilea announces license agreement for antibiotic Zevtera® (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.

Sep 12. 2017

Basilea announces distribution agreement with Cardiome to commercialize antibiotic Zevtera®/Mabelio® (ceftobiprole) in Europe and Israel

Aug 10. 2017

Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs

Jul 20. 2017

Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba® for Europe, Russia, Turkey and Israel

Jun 15. 2017

Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey and Israel

Jun 14. 2017

Basilea announces distribution agreement with Avir Pharma Inc. for Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) in Canada

Jun 13. 2017

Basilea awarded USD 54.8 million of additional funding by BARDA to support phase 3 development of ceftobiprole

Jun 12. 2017

Basilea announces clinical study agreement with Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma

Jun 06. 2017

Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting

Jun 02. 2017

Basilea names new member of its Extended Management Committee

Apr 28. 2017

Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders

Apr 21. 2017

Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections

Apr 06. 2017

Data presented at AACR meeting indicate diverse tumor-targeting properties of Basilea's BAL101553 and show a combination potential with bevacizumab

Feb 27. 2017

Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors

Feb 20. 2017

Basilea reports solid 2016 results and expects to double product sales in 2017

Dec 29. 2016

Basilea names new member of its Extended Management Committee

Dec 02. 2016

Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients

Nov 15. 2016

Basilea's antifungal Cresemba® (isavuconazole) launched in France

Sep 20. 2016

Basilea announces distribution agreement with Unimedic for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the Nordic countries

Sep 15. 2016

Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma

Sep 13. 2016

Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in Latin America

Sep 06. 2016

Basilea starts continuous infusion phase 1/2a clinical study with oncology drug candidate BAL101553

Aug 17. 2016

Basilea announces distribution agreement with Hikma for CRESEMBA® (isavuconazole) in the MENA region

Aug 15. 2016

Basilea reports 2016 half-year results - CRESEMBA® launched in key European markets

Jun 27. 2016

Basilea's antifungal CRESEMBA® (isavuconazole) launched in Italy

Jun 09. 2016

Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at ASCO meeting

Apr 22. 2016

Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders

Apr 21. 2016

Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at AACR meeting

Apr 20. 2016

Basilea awarded contract by BARDA of up to USD 100 million funding for ceftobiprole phase 3 program

Apr 15. 2016

Basilea reports presentation of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Mar 15. 2016

Basilea issues agenda for Annual General Meeting of Shareholders

Mar 09. 2016

Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA® (isavuconazole) open-label study for the treatment of mucormycosis

Mar 04. 2016

Basilea launching antifungal CRESEMBA® (isavuconazole) in Germany

Mar 03. 2016

Basilea launching antifungal CRESEMBA® (isavuconazole) in the United Kingdom

Feb 29. 2016

Basilea reports solid 2015 full-year results and is launching CRESEMBA®, its second hospital anti-infective, in Europe

Jan 22. 2016

GSK informs Basilea that it has elected not to continue its U.S. alitretinoin program

Dec 29. 2015

Basilea's Head of Global Human Resources, Heidi Mc Daid, to retire and Ursula Eberhardt named as successor

Dec 28. 2015

Basilea provides clinical program updates

Dec 19. 2015

Final allocations of Basilea CHF 200 million senior convertible bonds

Dec 10. 2015

Basilea successfully places CHF 200 million senior convertible bonds

Dec 10. 2015

Basilea successfully places CHF 200 million senior convertible bonds

Dec 09. 2015

Basilea launches a senior convertible bond issue

Nov 05. 2015

Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553

Oct 23. 2015

Basilea announces that European Commission maintained isavuconazole's orphan drug status

Oct 17. 2015

Basilea announces filing of registration statement for a proposed offering in the United States

Oct 16. 2015

Basilea announces that European Commission approves isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union

Oct 15. 2015

Basilea signs exclusive distribution agreement for Zevtera® (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC

Oct 12. 2015

Basilea announces that Health Canada approved ZEVTERA® for the treatment of bacterial lung infections

Sep 07. 2015

Basilea announces development of inhaled dosage form of its Gram-negative antibiotic BAL30072 as part of European iABC program

Aug 28. 2015

Basilea's Chief Technology Officer Dr. Ingrid Heinze-Krauss to retire and Dr. Günter Ditzinger named as successor

Aug 14. 2015

Basilea reports 2015 half-year results - Major milestones achieved for CRESEMBA® and Zevtera®

Aug 12. 2015

Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of lung and skin infections

Jul 30. 2015

Basilea reports topline results of isavuconazole phase 3 study in candidemia and other invasive Candida infections

Jul 24. 2015

Basilea announces that CHMP recommends approval of isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union

Jun 25. 2015

Basilea initiates phase 1/2a oncology study with oral formulation of tumor checkpoint controller BAL101553

May 05. 2015

Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor

Apr 29. 2015

Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders

Apr 24. 2015

Basilea reports isavuconazole and ceftobiprole data to be presented at ECCMID

Apr 01. 2015

Basilea in-licenses targeted cancer therapy

Mar 07. 2015

Basilea reports U.S. FDA approval of isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis

Feb 17. 2015

Basilea reports solid 2014 full-year results, preparing the ground for commercialization of Zevtera® in Europe

Jan 23. 2015

Basilea announces that FDA's Anti-Infective Drugs Advisory Committee recommends approval of isavuconazole for the treatment of invasive aspergillosis and mucormycosis

Dec 22. 2014

Swissmedic approves Basilea's antibiotic Zevtera® (ceftobiprole medocaril) for the treatment of pneumonia

Dec 05. 2014

Basilea announces launch of antibiotic Zevtera® (ceftobiprole medocaril) in Germany

Nov 21. 2014

Basilea reports that U.S. FDA sets date of Advisory Committee meeting on isavuconazole NDA for the treatment of invasive aspergillosis and mucormycosis

Nov 19. 2014

Basilea's oncology drug candidate BAL101553 induces significant anti-tumor effect in treatment-refractory tumor models

Nov 03. 2014

Basilea reports granting of U.S. orphan drug designation to isavuconazole for the treatment of invasive candidiasis

Oct 16. 2014

Basilea reports protocol amendment resulting in earlier completion of isavuconazole phase 3 invasive candidiasis study

Oct 09. 2014

Basilea reports that further subgroup and health economic analyses of isavuconazole phase 3 studies will be presented at IDWeek conference

Sep 06. 2014

Basilea's partner Astellas receives notification from U.S. FDA of acceptance of filing of isavuconazole NDA for the treatment of invasive aspergillosis and invasive mucormycosis

Sep 05. 2014

Extensive data presented on Basilea's anti-infectives isavuconazole, ceftobiprole and BAL30072 at ICAAC

Aug 21. 2014

European Medicines Agency accepts Basilea's isavuconazole Marketing Authorization Application for review

Aug 18. 2014

Basilea appoints Chief Commercial Officer

Aug 14. 2014

Basilea reports 2014 half-year financials - ceftobiprole launch in Germany planned for second half of 2014

Jul 21. 2014

Basilea to launch Zevtera®/Mabelio® (ceftobiprole medocaril) in Europe through a commercial services provider

Jul 17. 2014

Basilea submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections

Jul 17. 2014

Basilea reports that isavuconazole received QIDP designation from U.S. FDA for the treatment of invasive candidiasis

Jul 14. 2014

Basilea reports that isavuconazole receives orphan drug designations in Europe for the treatment of invasive mold infections

Jul 10. 2014

Basilea's partner Astellas submits isavuconazole U.S. NDA for the treatment of invasive aspergillosis and invasive mucormycosis

Jun 26. 2014

Basilea announces start of phase 2a study with oncology drug candidate BAL101553

Jun 25. 2014

Basilea provides update on ceftobiprole's U.S. regulatory status

Jun 13. 2014

Basilea initiates phase 1 combination study with its Gram-negative antibiotic BAL30072 and meropenem

Jun 12. 2014

Basilea initiates phase 1 combination study with its Gram-negative antibiotic BAL30072 and meropenem

Jun 02. 2014

Basilea's oncology drug candidate BAL101553 shows first evidence of antitumor activity in phase 1 study

May 14. 2014

Basilea reports additional data on positive isavuconazole phase 3 SECURE study at ECCMID

May 13. 2014

Basilea presents new data on its antibiotics pipeline at ECCMID

Apr 10. 2014

Resolutions of the Ordinary General Meeting of Shareholders of Basilea Pharmaceutica Ltd.

Apr 07. 2014

Basilea's oncology drug candidate BAL101553 demonstrates broad antitumor activity in treatment-resistant breast cancer models as presented at AACR

Feb 28. 2014

Basilea swaps its isavuconazole North American co-promote rights for full isavuconazole rights outside of North America

Feb 27. 2014

Basilea reports that isavuconazole receives Qualified Infectious Disease Product designation from U.S. FDA for the treatment of invasive mucormycosis

Feb 11. 2014

Basilea 2013 full-year results: strong operational and financial performance

Dec 03. 2013

Basilea reports that isavuconazole receives Qualified Infectious Disease Product (QIDP) designation from U.S. FDA for the treatment of invasive aspergillosis

Nov 18. 2013

Basilea reports isavuconazole orphan drug designation for treatment of zygomycosis by U.S. FDA

Nov 04. 2013

Basilea appoints new Chief Financial Officer

Oct 23. 2013

Basilea's antibiotic ceftobiprole obtains regulatory approval in Europe for pneumonia

Sep 30. 2013

Basilea reports positive topline phase 3 results for antifungal isavuconazole

Sep 16. 2013

Swissmedic accepts for review Basilea's ceftobiprole Marketing Authorization Application for the treatment of pneumonia

Sep 13. 2013

Basilea reports presentation of 19 posters at ICAAC on investigational anti-infectives isavuconazole, ceftobiprole, and BAL30072

Aug 21. 2013

Basilea reports 2013 half-year financials with improved operating results

Jul 17. 2013

Basilea provides update on isavuconazole phase 3 program

Jun 25. 2013

Basilea awarded contract by BARDA of up to USD 89 million for the development of its novel antibiotic BAL30072

Jun 04. 2013

Basilea presents first phase 1 data from its novel anti-cancer drug BAL101553 at ASCO conference

May 28. 2013

Basilea reports isavuconazole orphan drug designation by U.S. FDA

Apr 29. 2013

Basilea reports presentation of new data on anti-infective drug candidates addressing drug resistance

Apr 09. 2013

Resolutions of the Ordinary General Meeting of Shareholders of Basilea Pharmaceutica Ltd.

Mar 07. 2013

Basilea's Board proposes Martin Nicklasson to succeed Chairman Werner Henrich and recommends to shareholders that they do not support the request for a capital distribution at this time

Feb 23. 2013

Basilea receives request to place repayment of CHF 48 million from capital contribution reserve on the agenda of the ordinary general meeting of shareholders

Feb 07. 2013

Basilea reports 2012 financials with a solid cash position and significant milestones ahead